QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Recombinant human anti-VEGF IgG1 monoclonal antibody

5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

5-fluoro-2,4 (1H,3H)-pyrimidinedione

7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol

Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

omega-3 acid ethyl esters

cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

Stereotactic Body Radiation Therapy (SBRT)

Recombinant human super agonist IL-15 complex

Ad5 \[E1-, E2b-\]-HER2 vaccine

Ad5 \[E1-, E2b-\]-Brachyury vaccine

Ad5 \[E1-, E2b-\]-MUC1 vaccine

Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins

Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein

NK-92 \[CD16.158V, ER IL-2\]